Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

AZ/Alexion are also developing a follow-up Factor ... the positive readout bodes well for danicopan and ALXN-2050 in other uses with larger patient populations. Just as for previous schemes ...

While it’s always fun to play futurist, there are clues to business circa 2050 that can help strategists define their future business models and processes – not for 2050 but for the next 5-7 ...

Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Voydeya (danicopan). This first-in-class, oral ...

And the leaders, both of whom have served at the rare disease company Alexion, now owned by AstraZeneca, believe a small company approach is the way to get there. Even though funding isn’t at ...

Our research team assigns Neutral ratings to strategies they’re not confident will outperform a relevant index, or most peers, over a market cycle on a risk-adjusted basis. The series continues ...

Target-date portfolios provide diversified exposure to stocks, bonds, and cash for those investors who have a specific date in mind (in this case, the years 2046-2050) for retirement. These ...

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life ...

AstraZeneca on Saturday announced it was acquiring Alexion Pharmaceuticals for $39 billion, a deal aimed at boosting AstraZeneca's immunology and rare-disease research, combining the companies ...

A solid option for retirement savers. Our research team assigns Bronze ratings to strategies they’re confident will outperform a relevant index, or most peers, over a market cycle on a risk ...

Warning: This graphic requires JavaScript. Please enable JavaScript for the best experience. By 2050, over 5 billion people — probably more than half the planet’s ...

Global electricity demand is on track to double by 2050, mainly due to the scale of China’s monumental energy transition, according to a new report from the International Energy Agency.